



PRESS RELEASE

05 June 2024 10:00:00 CEST

AcouSort to participate in a pioneering project to release the potential in extracellular vesicles research

AcouSort is a member of the prestigious EVEREST project – a pioneering consortium in extracellular vesicle (EV) research, that recently received funding from the European union. The project brings together 22 institutions from 11 countries and is coordinated by University College Dublin. The interdisciplinary consortium is distinguished by an ambitious plan for over 285 months of staff exchanges, engaging at least 81 fellows.

The EVEREST project is all about expanding EV research and will focus on four key areas: standardized characterization and isolation of EVs; investigating EVs in Health or Disease and Enhancing Translational Biomarker Discovery; advancing EV-based therapeutics or drug delivery; and commercial development of EV-based technologies.

Within the framework of EVEREST, AcouSort will welcome external researchers from a variety of institutions around Europe to learn from their expertise and to educate them on the unique possibilities of acoustofluidics to significantly enhance speed and accuracy in an EV research setting.

As part of the project, AcouSort will also place some of its staff members on shorter secondments at institutions. During the secondments, they will be working with the AcouTrap to isolate novel sample types and to evaluate the output samples with new technologies, generation additional validation data for the AcouTrap system.

“The EVEREST project provides AcouSort with a truly fantastic opportunity to spread key knowledge and knowhow about our products and technology. The project will produce important data on the AcouTrap System which will be extremely beneficial in our efforts to establish this product as a state-of-the-art system for EV sample preparations,” says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com



PRESS RELEASE

05 June 2024 10:00:00 CEST

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).